The College of American Pathologists June 2021 release includes 88 revised cancer protocols and 3 new cancer protocols.

| **Group** | **Revised Cancer Protocols** | **Version** | **Changes** |
| --- | --- | --- | --- |
| Breast | Breast, Invasive, Resection | 4.5.0.0 | * General Reformatting * Revised Tumor Extent Section * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Breast | Breast, Invasive, Biopsy | 1.1.1.0 | * General Reformatting changes * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign add peds |
| Breast | Breast, DCIS, Resection | 4.4.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Node Section * Added Distant Metastasis Section * Removed pNX Staging Classification |
| Breast | Breast, DCIS, Biopsy | 1.0.1.0 | * General Reformatting * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign. |
| Breast | Breast, Biomarker | 1.4.1.0 | * General Reformatting |
| Central Nervous System | Brain/Spinal Cord | 4.0.0.0 | * No Changes |
| Endocrine | Adrenal Gland, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Appendix NET, Excision | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Modified Tumor Extent Question |
| Endocrine | Colon Rectum NET, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Duodenum/Ampulla NET, Resection | 1.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Jejunum/Ileum NET, Resection | 1.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Pancreas, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Stomach NET, Gastrectomy (Partial or Complete) | **4.1.0.0** | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Thyroid | **4.3.0.0** | * General Reformatting * Revised Clinical Section * Added Tumor Necrosis Question * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Endocrine | Thyroid Biomarker Reporting | **1.0.0.1** | * No Changes |
| Gastrointestinal | Ampulla Vater, Resection | **4.2.0.0** | * General Reformatting * Reformatted Tumor Extent * Revised Margins Section * Revise Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Anus, Excision | 4.2.0.0 | * General Reformatting * Reformatted Treatment Effect * Revised Margins Section * Removed pTX Staging Classification |
| Gastrointestinal | Anus, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Appendix, Excision | 4.2.0.0 | * General Reformatting * Updated Tumor Extent * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Colon and Rectum, Biopsy | 4.2.0.0 | * General Reformatting * Reformatted Lymphovascular Invasion Section * Reformatted Tumor Bud Question * Revised Margins Sections |
| Gastrointestinal | Colon and Rectum, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformatted Lymphovascular Invasion Section * Reformatted Tumor Bud Question |
| Gastrointestinal | Colon and Rectum Biomarker Reporting | 1.3.0.0 | * General Reformatting * Addition of HER2 Reporting |
| Gastrointestinal | Distal Extrahepatic Bile Ducts, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Esophagus, Surgical Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformatted Treatment Effect |
| Gastrointestinal | Gallbladder, Resection | 4.2.0.0 | * General Reformatting * Added Adenocarcinoma, NOS to Histologic Types * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Gastrointestinal Stromal Tumor (GIST), Biopsy | 4.2.0.0 | * General Reformatting |
| Gastrointestinal | Gastrointestinal Stromal Tumor (GIST), Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Gastrointestinal Stromal Tumor (GIST) Biomarker Reporting | 1.0.0.2 | * No Changes |
| Gastrointestinal | Hepatocellular, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformatted Vascular Invasion |
| Gastrointestinal | Intrahepatic Bile Ducts, Resection | 4.2.0.0 | * General Reformatting * Added New Histologic Type Cholangiocarcinoma, NOS * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Pancreas (Exocrine), Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformatted Treatment Effect * Reformatted Sites Involved by Direct Tumor Extension |
| Gastrointestinal | Perihilar Bile Duct, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Small Intestine, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gastrointestinal | Stomach, Resection | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformatted Treatment Effect * Revised Additional Findings |
| Gastrointestinal | Gastric HER2 Biomarker Reporting | **1.0.0.1** | * No Changes |
| General | DNA Mismatch Repair Biomarker Reporting | 1.0.0.2 | * General Reformatting |
| General | Generic Template, Biopsy | 1.0.1.0 | * General Reformatting |
| General | Generic Template, Resection | 1.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section |
| Genitourinary | Kidney, Biopsy | 4.1.0.0 | * General Reformatting * New Tumor Site Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Genitourinary | Kidney, Resection |  | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Genitourinary | Penis | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Genitourinary | Prostate, Resection | 4.2.0.0 | * General Reformatting * Histologic Grade Updated * New Section - IDC Incorporated into Grade * Cribriform Glands Question Updated * Tumor Quantitation Added * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pNX Staging Classification * Added Atypical Intraductal Proliferation (AIP) to Additional Findings |
| Genitourinary | Prostate TURP | 4.1.0.0 | * General Reformatting * Histologic Grade Updated * New Section - IDC Incorporated into Grade * Cribriform Glands Question Updated * Tumor Quantitation Added * Revised Margins Section * Atypical Intraductal Proliferation (AIP) to added Additional Findings * Equivocal response added to Periprostatic Fat Invasion and Seminal Vesicle Invasion |
| Genitourinary | Testis Radical Orchiectomy | 4.1.0.0 | * General Reformatting * Removed Prelymphadenectomy Treatment * Revised Lymph Nodes Section * Removed pNX Staging Classification |
| Genitourinary | Testis Lymphadenectomy | 4.1.0.0 | * General Reformatting * Added Histologic Types --- Yolk Sac Tumor and Mixed Germ Cell Tumor * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Genitourinary | Ureter, Renal Pelvis, Biopsy | 2.2.0.0 | * General Reformatting * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Genitourinary | Ureter, Renal Pelvis, Resection | 2.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Genitourinary | Urethra, Biopsy | 4.1.0.0 | * General Reformatting * Added LVI section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Genitourinary | Urethra, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Genitourinary | Urinary Bladder, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Reformat Tumor Extent Section |
| Genitourinary | Urinary Bladder, Biopsy | 4.1.0.0 | * General Reformatting |
| Gynecologic | Endometrium, Hysterectomy | 4.2.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * New WHO 5th Edition Histological Updates * Added Two-Tier Grading system (for endometrioid carcinomas only) * Added Depth of Cervical Invasion and Cervical Stroma Thickness Question * Updated Peritoneal / Ascitic Fluid Question * Updated Lymphovascular Invasion (LVI) Question |
| Gynecologic | Endometrium Biomarker Reporting | 1.2.01 | * No Changes |
| Gynecologic | Ovary, Fallopian Tube, Peritoneum | 1.2.0.0 | * General Reformatting * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Specimen Integrity Section Updated * Added Question on Uterine Integrity * New WHO 5th Edition Histological Updates * Reformatted Ovarian Surface and Fallopian Tube Surface Involvement * Updated Peritoneal / Ascitic Fluid Section * Deprecated Pleural Fluid * Added P53 Immunohistochemistry Under Special Studies * Deprecated BRCA1 and BRCA2 and DNA Mismatch Repair Enzyme Studies |
| Gynecologic | Trophoblastic Tumors | 4.1.0.0 | * General Reformatting * Deprecated Clinical History * Other Tissue / Organ Involvement * Added Equivocal Response to Lymphovascular Invasion (LVI) * Created Separate Distant Metastases Section * Removed pTX Staging Classification |
| Gynecologic | Uterine Cervix, Excision | 4.4.1.0 | * General Reformatting * Revisions to Depth of Stromal Invasion * Revised Other Tissue / Organ Involvement * Margin Status HSIL Changed to Multi-Select |
| Gynecologic | Uterine Cervix, Resection | 5.0.1.0 | * General Reformatting * Revisions to Depth of Stromal Invasion * Revised Other Tissue / Organ Involvement |
| Gynecologic | Uterine Sarcoma | 4.2.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Updated Other Tissue / Organ Involvement * Added Equivocal Response to Lymphovascular Invasion (LVI) * Added Tumor Site Question * Updated Peritoneal / Ascitic Fluid Involvement * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Gynecologic | Vagina, Biopsy | 4.3.0.0 | * General Reformatting * Updated Histologic Grade * New WHO 5th Edition Histological Updates * Revised Margins Section * Additional Findings Section Updated * Added p53 and p16 Immunohistochemistry plus HPV-ISH to Special Studies Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Gynecologic | Vagina, Resection | 4.3.0.0 | * General Reformatting * Updated Histologic Grade * New WHO 5th Edition Histological Updates * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Updated Wording for FIGO Stage * Additional Findings Section Updated * Added p53 and p16 Immunohistochemistry plus HPV-ISH to Special Studies Section * Modified Procedure |
| Gynecologic | Vulva | 4.2.0.0 | * General Reformatting * Updated Tumor General Modelling * Updated Histologic Grade Responses * New WHO 5th Edition Histological Updates * Added Equivocal Response to Lymphovascular Invasion (LVI) * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * Updated FIGO Stage * Additional Findings Section Updated * Added p53 and p16 Immunohistochemistry plus HPV-ISH to Special Studies Section |
| Head and Neck | Larynx | 4.1.0.0 | * Summary of Changes * General reformatting * Revised Margins section * Revised Lymph Node section * Added Distant Metastasis section * Removed pTX and pNX staging classifications |
| Head and Neck | Lip and Oral Cavity | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Node Section * Revised Tumor Site Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Head and Neck | Major Salivary Glands | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Revised Tumor Site Section * Added Macroscopic Tumor Extent * Added Distant Metastasis Section |
| Head and Neck | Nasal Cavity and Paranasal Sinuses | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Head and Neck | Pharynx | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Revised Tumor Site Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Head and Neck | Head and Neck Biomarker Reporting | 2.0.0.0 | * Complete Reformatting |
| Hematologic | Bone Marrow | 4.0.0.0 | * No Changes |
| Hematologic | Hodgkin Lymphoma | 3.1.0.1 | * No Changes |
| Hematologic | Non-Hodgkin Lymphoma | 3.2.0.1 | * No Changes |
| Hematologic | Plasma Cell Neoplasms | 1.0.0.2 | * No Changes |
| Ophthalmic | Retinoblastoma | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Removed pTX and pNX Staging Classification * Revised Tumor Site Section * Added Distant Metastasis Section |
| Ophthalmic | Uveal Melanoma | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Clinical Section * Revised Tumor Site Section * Added Tumor Sampling for Molecular Studies * Added Discrete Tumor Deposits to Orbit * Removed pTX and pNX Staging Classification * Added Special Studies Section |
| Other | Bone, Biopsy | 4.1.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates |
| Other | Bone, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification * New WHO 5th Edition Histological Updates |
| Other | Soft Tissue, Biopsy | 4.1.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Revised Margins Section |
| Other | Soft Tissue, Resection | 4.1.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Added Tumor Focality Question * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Pediatric | Ewing, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Revised Site Involved by Direct Tumor Extension * Cytogenic findings Remodeled * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Ewing, Biopsy | 4.1.0.0 | * General Reformatting * Revised Margins Section * Cytogenic Findings Remodeled * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Germ Cell Tumor, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * New Microscopic Coccyx Involvement Question * New Tumor Extent Question * New Immunohistochemistry Markers Added * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Germ Cell Tumor, Biopsy | 4.1.0.0 | * General Reformatting * Added Immunohistochemistry Markers to Special Studies * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Hepatoblastoma, Resection | 4.0.1.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Hepatoblastoma, Biopsy | 4.0.0.1 | * General Reformatting * Reformatted Special Studies Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Neuroblastoma, Resection | 4.1.0.0 | * General Reformatting * Made repeating question for nodular subtypes * Revised Lymph Nodes Section * Added Distant Metastasis Section * Update Pathologic Stage Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Neuroblastoma, Biopsy | 4.1.0.0 | * General Reformatting * Made repeating question for nodular subtypes * Update Pathologic Stage Section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Rhabdomyosarcoma, Resection | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Added new molecular studies section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Rhabdomyosarcoma, Biopsy | 4.1.0.0 | * General Reformatting * Revised Margins Section * Added new molecular studies section * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Wilms, Resection | 4.0.01 | * General Reformatting * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Pediatric | Wilms, Biopsy | 4.0.0.1 | * General Reformatting * Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign |
| Skin | Melanoma, Excision | 4.3.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Skin | Melanoma, Biopsy | 4.3.0.0 | * General Reformatting * Revised Margins Section * Removed pTX Staging Classification |
| Skin | Merkel | 4.1.0.0 | * General Reformatting * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pTX and pNX Staging Classification |
| Skin | Melanoma, Biomarker |  | * No Changes |
| Thorax | Lung, Resection | 4.2.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pNX Staging Classification |
| Thorax | Lung Biomarker Reporting | 2.0.0.0 | * Complete Reformatting |
| Thorax | Pleural Mesothelioma | 4.1.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Added Nuclear Atypia Score * Added Mitotic Count Score * Added Nuclear Grade * Added Necrosis * Added Histologic Grade * Revised Treatment Effect * Revised Margins Section * Revised Lymph Node Section * Removed pNX Staging Classification |
| Thorax | Thymus | 4.1.0.0 | * General Reformatting * New WHO 5th Edition Histological Updates * Revised Margins Section * Revised Lymph Nodes Section * Added Distant Metastasis Section * Removed pNX Staging Classification * Added Modified Masaoka Stage |
| **Group** | **New Reporting Protocol** |  |  |
| Genitourinary | Prostate Needle Biopsy Case Level | 1.0.0.0 | * New |
| Genitourinary | Prostate Needle Biopsy Specimen Level | 1.0.0.0 | * New |
| General | General IHC Quantitative Biomarkers | 1.0.0.0 | * New |